

Supplementary Table 1: Raw Score for Research Attention at the Two Main Liver Meetings				
Conference (year) (Raw values)	HCV	HBV	NAFLD	ALD
AASLD (2010)				
Symposia	2.5	0.5	0	0
Titles of sessions	11	6.5	3.5	2
Oral - general presentations	8	2	1	0
Oral - parallel presentations	7.5	8.5	2	2
Poster presentations	320.5	217.5	87	17
AASLD (2011)				
Symposia	1	0	0	0
Titles of sessions	15.5	8.5	7	2
Oral - general presentations	1.5	0.5	1	0
Oral - parallel presentations	6.5	1.5	2	2
Poster presentations	222	156	78.5	19
AASLD (2012)				
Symposia	2	1	0	1
Titles of sessions	17.5	6.5	5	2
Oral - general presentations	1.5	1.5	0	1
Oral - parallel presentations	2	1	2	1
Poster presentations	385.5	276.5	84	21
AASD (2013)				
Symposia	2	0.5	1.5	1.5
Titles of sessions	13.5	10.5	6	3
Oral - general presentations	1.5	0.5	0	0
Oral - parallel presentations	10	3.5	2	1
Poster presentations	379.5	270	98.5	33
AASLD (2014)				
Symposia	2	0	0.5	0.5
Titles of sessions	12	9	6	2
Oral - general presentations	2	0	0	0
Oral - parallel presentations	6	5	4	2
Poster presentations	400.5	215	142.5	45
EASL (2010)				
Symposia	13.875	4.625	1.75	1.25
Titles of sessions	9	6.25	3.125	2.625
Oral - general presentations	6.5	1.75	2.25	0.25
Oral - parallel presentations	4.125	3.25	1.625	1.375
Poster presentations	236.375	105.875	57.75	24.625
EASL (2011)				
Symposia	11	5	0	1
Titles of sessions	8	5	2	2
Oral - general presentations	4	0	1	1
Oral - parallel presentations	5	2	1	1
Poster presentations	265.5	119.5	67.5	17.5
EASL (2012)				

Symposia	9	5	1	1
Titles of sessions	9.5	4.5	1.5	1.5
Oral - general presentations	5.5	0.5	3	0
Oral - parallel presentations	3	4.5	1	1
Poster presentations	213	101	65	27
EASL (2013)				
Symposia	11.5	2.5	2	1
Titles of sessions	9.5	7.5	4	3
Oral - general presentations	7.5	2.5	3	0
Oral - parallel presentations	4.5	3.5	1.5	1.5
Poster presentations	312	123.5	69	36.5
EASL (2014)				
Symposia	24	6	4	2
Titles of sessions	9	8	5	4
Oral - general presentations	9	4	2	0
Oral - parallel presentations	4	3	3	2
Poster presentations	155	79.5	29.5	17.5
TOTAL	3182.875	1810.75	866.5	308.625
Abbreviations: HCV - Hepatitis C Virus, HBV - Hepatitis B Virus, NAFLD - Non-Alcoholic Fatty Liver Disease, ALD - Alcoholic Liver Disease.				

Supplementary table 2: Drugs in Development Pipelines of 38 Major Pharmaceutical Companies

Pharmaceutical Companies	HCV	HBV	NAFLD	ALD
Abbott Laboratories	28	2	0	1
Gilead	8	4	2	0
Johnson & Johnson	4	0	0	0
Merck & Co	5	0	0	0
Roche	4	0	0	0
Bristol-Myers Squibb	3	3	0	0
GlaxoSmithKline	4	0	0	0
Vertex	2	0	0	0
Novartis	1	0	0	0
Astellas Pharma US, Inc	0	0	0	0
Bayer Health Care	0	0	0	0
Boehringer Ingelheim Pharmaceutical, Inc	0	0	0	0
Eli Lilly	0	0	0	0
Pfizer	0	0	0	0
Salix	0	0	0	0
CSL	0	0	0	0
Chugai Pharmaceutical Co.	0	0	0	0
Biogen Idec	0	0	0	0
Otsuka Pharmaceutical	0	0	0	1
Mitsubishi Pharma	2	0	0	0
Dainippon Sumitomo Pharma	0	0	0	0
Kyowa Hakko	0	0	0	0
Shionogi	0	0	0	0
Mylan Laboratories	0	0	0	0
H. Lundbeck	0	0	0	0
Daiichi Sankyo	0	0	0	0
Novo Nordisk	0	0	0	0
Valeant Pharmaceuticals	0	0	0	0
Eisai	0	0	0	0
Merck KGaA	0	0	0	0
AbbVie	0	0	0	0
UCB	0	0	0	0
Genzyme	0	0	0	0
Baxter International	0	0	0	0
Teva Pharmaceutical Industries	0	0	0	0
Amgen	0	0	0	0
Takeda Pharmaceuticals Co	0	0	0	0
Sanofi	0	0	0	0
Astrazeneca	0	0	0	0

*Drugs not specifically allocated to the liver disease etiologies were not included.

Supplementary Table 3: Total Number of Research Opportunities in Europe and the U.S.				
Raw Values for Research Opportunities in Europe and U.S.				
	HCV	HBV	NAFLD	ALD
NIH	738	328	300	47
CORDIS	52.5	25.5	6	0
Registered Clinical Trials				
	407	461	235	66
Scientific articles from PubMed				
	15438	10724	5518	1728

Supplementary Table 4: Major Liver Disease's Burden				
Raw Values for Liver Disease's Burden				
	HCV	HBV	NAFLD	ALD
OLT-EU (%)	28	10.5	10	38.5
OLT-US (%)	40.05	#	15.8	23.15
*Cause of Cirrhosis (n, %)	46, 46.5%	3, 3.0%	27, 27.3%	25, 25.3%
**Cause of fibrosis (n, %)	8, 8.99%	5, 5.62%	37, 41.6%	27, 30.3%
Mortality US (%)	22.82	0.54	2.65	49.62
Hospitalization Cost	\$167,785	\$52,062	\$45,755	\$848,189
Patient Admissions and Discharges (n)	14749	4568	2858	64752
*Based on a sample size of 99 subjects				
** Based on a sample size of 1358 subjects, 89 subjects had LSM >8kPa				
# Due to the significantly decreasing incidence of HBV Wong et al did not include that data				

Supplementary Table 5: Published Clinical Trials from 2010- 2014

Published Clinical Trials from 2010- 2014						
NEJM	2010	2011	2012	2013	2014	Total
HCV	1	6	1	6	11	25
HBV	0	1	0	0	0	1
NAFLD	0	0	0	0	0	0
ALD	0	2	0	0	0	2
LANCET	2010	2011	2012	2013	2014	Total
HCV	2	0	1	6	9	18
HBV	0	0	2	2	2	6
NAFLD	1	0	0	0	2	3
ALD	0	0	0	0	0	0
ANNALS	2010	2011	2012	2013	2014	Total
HCV	0	0	0	0	0	0
HBV	0	0	0	0	0	0
NAFLD	0	0	0	0	0	0
ALD	0	0	0	0	0	0
JAMA	2010	2011	2012	2013	2014	Total
HCV	0	0	2	2	2	6
HBV	0	1	0	0	1	2
NAFLD	0	1	0	0	0	1
ALD	0	0	0	1	0	1
Gastroenterology	2010	2011	2012	2013	2014	Total
HCV	16	10	6	8	14	54
HBV	3	3	5	2	3	16
NAFLD	1	0	1	2	1	5
ALD	0	0	0	0	2	2
Gut	2010	2011	2012	2013	2014	Total
HCV	4	1	3	3	3	14
HBV	3	3	2	2	2	12
NAFLD	2	1	0	0	0	3
ALD	0	0	0	0	0	0
J Hepatology	2010	2011	2012	2013	2014	Total
HCV	3	2	4	13	7	29
HBV	3	3	1	5	4	16
NAFLD	0	1	0	1	0	2
ALD	0	1	0	0	0	1
Hepatology	2010	2011	2012	2013	2014	Total
HCV	6	9	7	6	9	37
HBV	4	4	1	3	3	15
NAFLD	0	1	1	0	0	2
ALD	0	0	0	0	0	0